Laidlaw Reiterates $18.00 Price Target for Flexion Therapeutics (FLXN)

Flexion Therapeutics (NASDAQ:FLXN) has been given a $18.00 price target by Laidlaw in a report released on Thursday, TipRanks reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Laidlaw’s price objective points to a potential upside of 71.27% from the stock’s previous close.

FLXN has been the subject of a number of other reports. BidaskClub raised shares of Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 5th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Wednesday. Northland Securities reaffirmed a “buy” rating and set a $20.00 price objective on shares of Flexion Therapeutics in a research report on Friday, March 1st. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. Finally, ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $22.64.

FLXN stock traded down $0.49 during midday trading on Thursday, reaching $10.51. 826,480 shares of the company were exchanged, compared to its average volume of 798,515. The company has a debt-to-equity ratio of 1.35, a current ratio of 7.78 and a quick ratio of 7.58. Flexion Therapeutics has a one year low of $9.90 and a one year high of $29.10. The stock has a market cap of $417.92 million, a price-to-earnings ratio of -2.34 and a beta of 1.68.

In other Flexion Therapeutics news, insider Michael D. Clayman bought 4,046 shares of Flexion Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was bought at an average price of $12.36 per share, with a total value of $50,008.56. Following the completion of the transaction, the insider now owns 70,856 shares in the company, valued at approximately $875,780.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 14.59% of the company’s stock.

Several institutional investors have recently made changes to their positions in FLXN. Point72 Asset Management L.P. bought a new stake in shares of Flexion Therapeutics in the third quarter valued at about $23,768,000. Capital International Investors bought a new stake in shares of Flexion Therapeutics in the third quarter valued at about $12,162,000. Selz Capital LLC bought a new stake in shares of Flexion Therapeutics in the first quarter valued at about $3,619,000. D. E. Shaw & Co. Inc. boosted its position in shares of Flexion Therapeutics by 516.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 250,402 shares of the specialty pharmaceutical company’s stock valued at $2,835,000 after acquiring an additional 209,809 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Flexion Therapeutics in the fourth quarter valued at about $849,000. 94.73% of the stock is owned by institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: How to Use the New Google Finance Tool

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.